- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval…
Total Revenue of $69.9 Million, an increase of 12.9% YoY Net Loss of $12.4 Million, an improvement of 37.0% YoY…
SAN FRANCISCO, May 12, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical…
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with…
CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage…
Elite Body Sculpture London 1 51 Harley Exterior Elite Body Sculpture London 2 51 Harley InteriorMIAMI BEACH, Fla., May 12,…
At the annual general meeting (the “AGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 12 May 2023…
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or…
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on…